Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.48 |
| ▸ | HTR1A | P08908 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alcohol SCHEMBL5238742 | 0.84 | MTNR1A (0.63) | MTNR1AHTR1AHTTSLC6A4 | |
| SCHEMBL9239494 | 0.83 | MTNR1A (0.47) | MTNR1AHTR1AKMT2ATDP1L3MBTL1 | |
| SCHEMBL5871763 | 0.82 | MTNR1A (0.46) | MTNR1AHTR1AKMT2ATDP1L3MBTL1 | |
| SCHEMBL9236154 | 0.82 | MTNR1A (0.48) | MTNR1AHTR1AKMT2ATDP1L3MBTL1 | |
| SCHEMBL13534270 | 0.82 | MTNR1A (0.50) | MTNR1AHTR1AKMT2ATDP1L3MBTL1 | |
| SCHEMBL25335293 | 0.82 | HTR1B (0.46) | MTNR1AHTR1AKMT2ATDP1L3MBTL1 | |
| SCHEMBL9238978 | 0.81 | MTNR1A (0.47) | MTNR1AHTR1AKMT2ATDP1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL25334638 | 0.81 | HTR1B (0.45) | MTNR1AHTR1AKMT2ATDP1L3MBTL1 | |
| SCHEMBL10339701 | 0.81 | MTNR1A (0.50) | MTNR1AHTR1AKMT2ATDP1L3MBTL1 | |
| SCHEMBL13533396 | 0.80 | MTNR1A (0.48) | MTNR1AHTR1AKMT2ATDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108947799-A | A kind of preparation method of chlorobenzene oxycarboxylic acid | 山东润博生物科技有限公司 | 2018-12-07 | — | — | CN | disclosed |
| US-7534794-B2 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM AB (SE) | 2009-05-19 | — | — | US | disclosed |
| US-7071180-B2 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM AB (SE) | 2006-07-04 | — | — | US | disclosed |
| EP-1178973-B1 | PYRAZINYL-PIPERAZINE- COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2005-12-21 | — | — | EP | disclosed |
| US-20040242554-A1 | CERTAIN ARYLALIPHATIC AND HETEROARYL-ALIPHATIC PIPERAZINYL PYRAZINES AND THEIR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES | BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION | 2004-12-02 | — | — | US | disclosed |
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION | 2003-05-15 | — | — | US | disclosed |
| US-6465467-B1 | DISEASES RELATED TO THE 5-HT2C RECEPTOR, ESPECIALLY EATING, MEMORY, MOOD, URINARY AND ANXIETY DISORDERS, SCHIZOPHRENIA, PAIN, SEXUAL DYSFUNCTIONS | BIOVITRUM AB (SE) | 2002-10-15 | — | — | US | disclosed |
| EP-1178973-A2 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | Pharmacia AB (SE) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000076984-A2 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | HTR2C, HTR3C, HTR2A | MTNR1A 156/4885HTR1A 5/4885KMT2A 1494/4885 |
| US-20040242554-A1 | CERTAIN ARYLALIPHATIC AND HETEROARYL-ALIPHATIC PIPERAZINYL PYRAZINES AND THEIR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES | HTR2C, HTR3C, HTR2A | MTNR1A 159/4885HTR1A 5/4885KMT2A 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.